Sort
59,101 grants matching “hypertension”
HIMF/FIZZ1 IN PULMONARY HYPERTENSION/RIGHT HEART FAILURE
$462,647Roger A Johns · Johns Hopkins University · P50 · FY2007 · HL
Targeted sympathetic ablation for treatment of hypertension
$462,646John W Osborn · University Of Minnesota · R01 · FY2015 · HL
Ca2+ Regulation in Newly Formed Ventricular Myocytes
$462,500Temple University · R01 · FY2005 · HL
Determining Processes of Cardiovascular Care Relevant to Complex Patients
$462,430Elizabeth A Bayliss · Kaiser Foundation Research Institute · R21 · FY2010 · HS
Impact of Clonal Hematopoiesis on the Progression of Kidney Disease
$462,396Cassianne Robinson-Cohen · Vanderbilt University Medical Center · R01 · FY2025 · DK
Regulation of Angiogenesis and Renin Expression in Rats
$462,303Andrew S. Greene · Medical College Of Wisconsin · P01 · FY2007 · HL
Integrating Hypertension and Cardiovascular Disease Care into Existing HIV Service Package in Botswana (InterCARE)-Statin Sub-study
$462,277Mosepele Mosepele · University Of Botswana · R01 · FY2025 · HL
AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSIO
$462,254University Of Texas Sw Med Ctr/Dallas · U01 · FY2001 · DK
Genetics of Chronic Kidney Disease
$462,224Stephen T Turner · Mayo Clinic Rochester · R01 · FY2010 · DK
Optimizing Display of Blood Pressure Data to Support Clinical Decision Making
$462,179Richelle J Koopman · University Of Missouri-Columbia · R01 · FY2018 · HS
Environmental &Genetic Risk Factors for Renal Function
$462,152Johns Hopkins University · R01 · FY2003 · ES
HYPERGEN: GENETICS OF LEFT VENTRICULAR HYPERTROPHY
$462,136University Of Minnesota Twin Cities · R01 · FY2003 · HL
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
$462,132Mara Lorenzi · Schepens Eye Research Institute · R01 · FY2011 · EY
Mechanisms of CLC Transporters and Channels
$462,124Merritt C Maduke · Stanford University · R01 · FY2016 · GM
RGS Protein Function and Regulation
$462,023Kendall Jay Blumer · Washington University · R01 · FY2007 · HL
Multifactor Risk Reduction for Optimal Management in Peripheral Arterial Disease
$462,013Roberta K Oka · University Of California, San Francisco · R01 · FY2010 · NR
Comparison of RAS inhibitor classes for cerebrovascular management in hypertensive patients who contracted COVID-19 infection
$462,000David H Salat · Massachusetts General Hospital · R21 · FY2021 · AG
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage
$461,999Magdy H Selim · Beth Israel Deaconess Medical Center · R01 · FY2008 · NS
RGS Protein Function and Regulation
$461,962Kendall Jay Blumer · Washington University · R01 · FY2006 · HL
Using Information Technology to Provide Measurement Based Care for Chronic Illnes
$461,911Madhukar H Trivedi · Ut Southwestern Medical Center · R18 · FY2007 · HS
NTSHSD2 neuron activity: regulation by aldosterone and afferent controlâ
$461,889Jon Resch · University Of Iowa · R01 · FY2025 · NS
Research Project
$461,870Monica L. Baskin · University Of Alabama At Birmingham · U54 · FY2013 · CA
Siblings With Ischemic Stroke Study (SWISS)
$461,786James F Meschia · Mayo Clinic Jacksonville · R01 · FY2006 · NS
Cyclophilin A is a Novel Mediator of Pulmonary Arterial Hypertension
$461,786Bradford C Berk · University Of Rochester · R01 · FY2017 · HL
Cyclophilin A is a Novel Mediator of Pulmonary Arterial Hypertension
$461,786Bradford C Berk · University Of Rochester · R01 · FY2019 · HL